Policy
FDA Panel to Weigh GRAIL's Galleri, the First Multi-Cancer Blood Test Up for U.S. Approval
GRAIL shares jumped Monday ahead of Wednesday's advisory committee vote. The company's data show a test that finds cancers standard screening misses — and a randomized trial that missed its main goal.
ME
By Marcus Elrod
Sep 21, 2026 · 3 min read
Shares of GRAIL Inc. rose sharply Monday, two days before a Food and Drug Administration advisory panel meets to review the company's Galleri blood test, which would be the first test approved in the U.S. to screen for many types of cancer at once.
Discussion (0)
Sign in to join the discussion.
Loading comments…
ME
Marcus Elrod
Marcus tracks positioning, flows and rates. He writes CI's weekly market internals column.
Marcus Elrod writes for Corporate Insider Inc.